Perrigo Co Plc’s shareholders rejected Mylan NV’s $26 billion hostile bid, ending the Netherlands-based generic drug maker’s seven-month pursuit of its smaller rival. Mylan’s offer expired on Friday with just 40 per cent of Perrigo shares tendered, below the required minimum 50 per cent, ensuring victory for Perrigo...
↧